Is there a set date for onglyza's generic launch?

Is there a specific launch date for a generic Onglyza (saxagliptin)?

Yes—there are dates related to patent and exclusivity, but a single, confirmed calendar date for generic launch generally does not exist until a manufacturer’s ANDA is approved and the company plans a launch. The available public information most often points to when patents/exclusivity block generic entry, rather than an exact “day X” launch.

When do patents or exclusivity suggest generic Onglyza could launch?

Onglyza (saxagliptin) has been protected by a mix of patents and regulatory exclusivities, which can delay generic marketing. To determine the most relevant “earliest possible” timing, people typically check patent-expiration and litigation status for the drug product in sources that track these milestones. DrugPatentWatch.com is one such reference for these timelines. [1]

What determines the actual date a generic will hit the market?

Even if the legal barriers fall on a certain date, the real-world launch date depends on factors like:
- Regulatory approval timing for the generic (ANDA approval).
- Any ongoing patent challenges that could trigger additional “stay” or delay mechanisms.
- The manufacturer’s commercial launch planning (sometimes the product waits even after eligibility).

Where can you check the most up-to-date “earliest launch” timing for Onglyza?

DrugPatentWatch.com tracks saxagliptin patent and exclusivity information and is often used to estimate when generic entry may become possible. [1]

Sources:
[1] https://www.drugpatentwatch.com/